RxDoctor Payments Data

Charles Cobb, MD

Urology · Jacksonville, FLNPI 1083752000

Payments from drug & device makers

$5,029in general payments, 2019–2025

Across 135 payments — averaging $37.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$2K
  • Procept Biorobotics Corporation$617
  • Astellas Pharma US Inc$393
  • Myriad Genetic Laboratories, Inc.$319
  • Teleflex LLC$287
  • Boston Scientific$215
  • plus $1K from 28 others

What the payments were for

  • Travel & lodging$1,57431%
  • Food & beverage$3,35467%
  • Education$1012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,029 in reported general payments places this provider in the 55th percentile of 935 urology providers in Florida.

See all urology providers in Florida

Medicare billing

Part B allowed, 2024
$476,927
Medicare patients
1,253
Services billed
11,789

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron90$100,456
GemtesaVibegron38$32,864
Tamsulosin Hcl772$11,979
Potassium Citrate ErPotassium Citrate66$7,383
Finasteride316$4,818
Tolterodine Tartrate ErTolterodine Tartrate49$4,078
Testosterone17$3,356
Alfuzosin Hcl ErAlfuzosin Hcl86$2,252
Gentamicin Sulfate21$2,176
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst133$1,670
Silodosin13$1,588
Estradiol19$1,585
Solifenacin Succinate29$879
Oxybutynin Chloride21$700
Bethanechol Chloride11$537

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$393$100,45690 claims
Sumitomo Pharma America, Inc.Gemtesa$38$32,86438 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 935 urology providers in Florida.

Other urology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →